Literature DB >> 11590327

Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas.

F C Brunicardi1, R Kleinman, S Moldovan, T H Nguyen, P C Watt, J Walsh, R Gingerich.   

Abstract

INTRODUCTION: In this study, immunoneutralization of endogenous insulin, glucagon, and somatostatin with specific antibodies was used in an isolated perfused human pancreas (IPHP) model. AIMS: To study intrapancreatic cellular interactions and pancreatic hormonal secretion.
METHODOLOGY: Randomized, sequential 10-minute test intervals of single-pass perfusion with each antibody were performed at 3.9 mM or 11.5 mM steady-state glucose concentrations. Somatostatin, insulin, and glucagon levels were measured in the effluent during basal and immunoneutralization intervals.
RESULTS: At 3.9 mM glucose concentration, somatostatin antibody (SS-Ab) stimulated insulin and glucagon secretion, insulin antibody (IN-Ab) inhibited glucagon secretion, and glucagon antibody (GN-Ab) stimulated insulin secretion. At 11.5 mM glucose concentration, SS-Ab stimulated insulin secretion, IN-Ab stimulated glucagon and inhibited somatostatin secretion, and GN-Ab stimulated insulin secretion.
CONCLUSION: The variation in hormonal responses to immunoneutralization during stimulated and nonstimulated glucose conditions suggests that a dynamic association exists between the pancreatic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590327     DOI: 10.1097/00006676-200110000-00012

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  24 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  Paracrine regulation of glucagon secretion: the β/α/δ model.

Authors:  Margaret Watts; Joon Ha; Ofer Kimchi; Arthur Sherman
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-02-02       Impact factor: 4.310

3.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

4.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

5.  Can somatostatin antagonism prevent hypoglycaemia during exercise in type 1 diabetes?

Authors:  Nadine Taleb; Rémi Rabasa-Lhoret
Journal:  Diabetologia       Date:  2016-05-06       Impact factor: 10.122

6.  Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells.

Authors:  M Braun; R Ramracheya; S Amisten; M Bengtsson; Y Moritoh; Q Zhang; P R Johnson; P Rorsman
Journal:  Diabetologia       Date:  2009-05-14       Impact factor: 10.122

7.  Insulin reciprocally regulates glucagon secretion in humans.

Authors:  Benjamin A Cooperberg; Philip E Cryer
Journal:  Diabetes       Date:  2010-08-23       Impact factor: 9.461

Review 8.  New insights into the architecture of the islet of Langerhans: a focused cross-species assessment.

Authors:  Rafael Arrojo e Drigo; Yusuf Ali; Juan Diez; Dinesh Kumar Srinivasan; Per-Olof Berggren; Bernhard O Boehm
Journal:  Diabetologia       Date:  2015-07-28       Impact factor: 10.122

9.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

10.  Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans.

Authors:  Benjamin A Cooperberg; Philip E Cryer
Journal:  Diabetes Care       Date:  2009-09-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.